EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease

Min Soo Cho, Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park und 13 weitere

New England Journal of Medicine · 05.12.2024 · 391 (22) · 2075-2086

DOI: 10.1056/nejmoa2407362 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 05.12.2024. Verfasst von Min Soo Cho und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Cardiology (M.S.C., D.-Y.K., J.-M.A., S.-J.P., D.-W.P., G.-B.N.) and the Division of Biostatics (S.-C.Y.), Asan Medical Center…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Coronary Artery Disease, Factor Xa Inhibitors, Hemorrhage. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Cardiovascular Research Foundation, Daiichi-Sankyo, Daewoong Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCoronary Artery DiseaseFactor Xa InhibitorsHemorrhagePlatelet Aggregation InhibitorsPyridinesThiazolesAgedAged, 80 and overFemaleHumansMaleMiddle AgedDrug Therapy, CombinationEmbolismIncidenceKaplan-Meier EstimateMyocardial InfarctionRepublic of KoreaStrokeTreatment Outcome

Substanzen

edoxabanFactor Xa InhibitorsPlatelet Aggregation InhibitorsPyridinesThiazoles

Autor:innen und Institutionen

  • From the Department of Cardiology (M.S.C., D.-Y.K., J.-M.A., S.-J.P., D.-W.P., G.-B.N.) and the Division of Biostatics (S.-C.Y.), Asan Medical Center, University of Ulsan College of Medicine, the Department of Cardiolog…

ORCID-Profile: Ki-Hun Kim, Duk-Woo Park

Förderung

  • Cardiovascular Research Foundation
  • Daiichi-Sankyo
  • Daewoong Pharmaceutical Company

Zitieren

APA

Cho, M. S., Kang, D. Y., Ahn, J. M., Yun, S. C., Oh, Y. S., Lee, C. H., Choi, E. K., Lee, J. H., Kwon, C. H., Park, G. M., Choi, H. O., Park, K. H., Park, K. M., Hwang, J., Yoo, K. D., Cho, Y. R., Kim, J. H., Hwang, K. W., Jin, E. S., …, & EPIC-CAD Investigators (2024). Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. New England Journal of Medicine, 391(22), 2075-2086. https://doi.org/10.1056/nejmoa2407362

Vancouver

Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. New England Journal of Medicine. 2024;391(22):2075-2086. doi:10.1056/nejmoa2407362

BibTeX
@article{Cho2024,
  author = {Cho, Min Soo and Kang, Do-Yoon and Ahn, Jung-Min and Yun, Sung-Cheol and Oh, Yong-Seog and Lee, Chang Hoon and Choi, Eue-Keun and Lee, Ji Hyun and Kwon, Chang Hee and Park, Gyung-Min and Choi, Hyung Oh and Park, Kyoung-Ha and Park, Kyoung-Min and Hwang, Jongmin and Yoo, Ki-Dong and Cho, Young-Rak and Kim, Ji Hyun and Hwang, Ki Won and Jin, Eun-Sun and Kwon, Osung and Kim, Ki-Hun and Park, Seung-Jung and Park, Duk-Woo and Nam, Gi-Byoung and EPIC-CAD Investigators, EPIC-CAD Investigators},
  title = {Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {22},
  pages = {2075--2086},
  doi = {10.1056/nejmoa2407362}
}
Kostenlos starten →